Amish-Backed Gene Therapy Company, Plowshare Therapies, Raises $6.7 Million
The funding will support manufacturing, safety testing and regulatory preparations for an experimental gene therapy targeting types 1A and 1B of Maple Syrup Urine Disease.
Key Points
- Plowshare Therapies has raised $6.7 million to advance PLOW-101, its investigational dual-gene therapy for maple syrup urine disease (MSUD) types 1A and 1B.
- The program is in Investigational New Drug (IND) application preparation and holds FDA Orphan Drug and Rare Pediatric Disease designations.
- Plowshare has entered into agreements with a specialized manufacturing partner for process development and gene therapy manufacturing.
Plowshare Therapies, a biotechnology company developing gene therapies for severe pediatric rare diseases, announced that it has raised $6.7 million to advance PLOW-101, its investigational dual-gene therapy for maple syrup urine disease (MSUD) types 1A and 1B. The funding supports the program’s transition from preclinical research into manufacturing and development work needed for an Investigational New Drug (IND) application.
Stay updated on Gene Therapy news
Thanks! Your signup has been saved.
Plowshare has completed its current fundraising initiative. The capital is being deployed against defined development milestones, including manufacturing, toxicology, and regulatory work required to move PLOW-101 toward an IND application. The program is in IND preparation and holds FDA Orphan Drug and Rare Pediatric Disease designations.
PLOW-101 is designed to deliver both BCKDHA and BCKDHB, the two genes encoding the catalytic components of the branched-chain 2-ketoacid dehydrogenase complex, using an adeno-associated virus serotype 9 (AAV9) vector. The program builds on peer-reviewed dual-gene rescue research published in Science Translational Medicine in 2025 and on decades of clinical experience caring for children with MSUD in Lancaster County.
As part of its IND-enabling development work, Plowshare has entered into agreements with a specialized manufacturing partner to support process development and AAV manufacturing under Good Manufacturing Practice (GMP) standards for the MSUD gene therapy program.
Rather than building a large internal infrastructure, Plowshare works with specialized partners and links capital deployment to predefined evidence milestones. The company describes its mission-locked structure as designed to align scientific progress, financial stewardship, and patient access as programs advance.
MSUD
MSUD is a life-threatening inherited metabolic disorder that prevents the body from properly breaking down branched-chain amino acids. The disease occurs worldwide but is concentrated in several founder populations, including Old Order Mennonite communities in Pennsylvania, where incidence is approximately one in 380 births. Plowshare’s approach grew from more than two decades of direct clinical care for families affected by MSUD in Lancaster County.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
Similar stories
Kolon’s Cell-Based Gene Therapy Fails Phase 3 Osteoarthritis Trial
CIRM Approves $662M Regen Med Funding, Largest in its History
FDA Reverses Decision on Regenxbio’s Gene Therapy for Hunter’s Syndrome, Supporting BLA Resubmission for Accelerated Approval
Altman-Backed Regenerative Medicine Startup, Retro Biosciences, Closes Funding Round at $1.8B Valuation
Sana Biotechnology and Mayo Clinic Partner Up on Type 1 Diabetes Stem Cell-Derived Therapy, Phase 1 Potentially This Year
Dark Horse Consulting Group and KunTuo Team Up To Accelerate Cell & Gene Therapy Trials In China
Latus Bio Nabs $97 Million to Continue Neurodegenerative Gene Therapy Pipeline
Regeneron Nabs Deal with White House, New Gene Therapy Will Be Free
